Penn Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Penn Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.2M	Buy	207,362 +27,646	+15%	+$2.22M	1.09%	43
2026 Q1	$13.8M	Buy	179,716 +42,322	+31%	+$3.3M	1.07%	53
2025 Q4	$10.9M	Buy	137,394 +131,030	+2,059%	+$11.3M	0.87%	66
2025 Q3	$583K	Buy	6,364 +387	+6%	+$31.6K	0.04%	140
2025 Q2	$390K	Sell	5,977 -719	-11%	-$46.8K	0.03%	138
2025 Q1	$448K	Buy	+6,696	New	+$400K	0.04%	129
2014 Q4	–	Sell	-143,220	Closed	-$4.05M	–	295
2014 Q3	$4.05M	Sell	143,220 -110	-0.1%	-$3.3K	0.17%	166
2014 Q2	$4.94M	Buy	143,330 +25,086	+21%	+$787K	0.19%	150
2014 Q1	$3.71M	Buy	+118,244	New	+$3.14M	0.14%	168

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Penn Capital Management's ANIP Position: Q2 2026 in Review

Penn Capital Management increased its ANI Pharmaceuticals (ANIP) stake by 15% in Q2 2026, buying an estimated $2.22M and bringing the position to 207,362 shares worth $17.2M. The position accounts for 1.09% of the portfolio, ranked #43.

Penn Capital Management first reported a position in ANIP in Q1 2014 and has held it in 9 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Penn Capital Management held 207,362 shares of ANI Pharmaceuticals worth $17.2M as of Q2 2026.
Penn Capital Management bought 27,646 ANI Pharmaceuticals shares in Q2 2026, an estimated $2.22M.
ANI Pharmaceuticals made up 1.09% of Penn Capital Management's portfolio in Q2 2026, its #43 holding.
Penn Capital Management first reported a position in ANI Pharmaceuticals in Q1 2014 and has held it in 9 quarters since.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.